Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia.
(2006) In Haemophilia 12 Suppl 3. p.52-60- Abstract
- The formation of inhibitory alloantibodies is, in the postinfectious era, the most severe and costly complication of replacement therapy in patients with haemophilia. The complexity of the immune response to the infused factor becomes more and more obvious as knowledge in the area increases. Antibodies develop as a result of a complex multi-factorial interaction between antigen-presenting cells, T- and B-lymphocytes. Genetic susceptibility of cell surface molecules, such as the major histocompatibility complex, the T-cell receptor and cytokine receptors, as well as various immunomodulatory molecules have a major impact on the outcome. In addition, environmental factors probably influence the risk of inhibitor development. The current... (More)
- The formation of inhibitory alloantibodies is, in the postinfectious era, the most severe and costly complication of replacement therapy in patients with haemophilia. The complexity of the immune response to the infused factor becomes more and more obvious as knowledge in the area increases. Antibodies develop as a result of a complex multi-factorial interaction between antigen-presenting cells, T- and B-lymphocytes. Genetic susceptibility of cell surface molecules, such as the major histocompatibility complex, the T-cell receptor and cytokine receptors, as well as various immunomodulatory molecules have a major impact on the outcome. In addition, environmental factors probably influence the risk of inhibitor development. The current concept of inhibitor development is reviewed. A better understanding of the pathophysiological mechanisms involved will facilitate improvement of therapy in the future, and hopefully provide an opportunity to prevent this complication of treatment. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/156907
- author
- Astermark, Jan LU
- organization
- publishing date
- 2006
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- inhibitors, risk factors, genotype, haemophilia
- in
- Haemophilia
- volume
- 12 Suppl 3
- pages
- 52 - 60
- publisher
- Wiley-Blackwell
- external identifiers
-
- wos:000237117700008
- scopus:33646140127
- ISSN
- 1351-8216
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Emergency medicine/Medicine/Surgery (013240200)
- id
- 5b07d233-ad00-4c70-899b-9b32d69f3859 (old id 156907)
- alternative location
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16683997&dopt=Abstract
- date added to LUP
- 2016-04-01 12:02:18
- date last changed
- 2022-07-29 21:25:44
@article{5b07d233-ad00-4c70-899b-9b32d69f3859,
abstract = {{The formation of inhibitory alloantibodies is, in the postinfectious era, the most severe and costly complication of replacement therapy in patients with haemophilia. The complexity of the immune response to the infused factor becomes more and more obvious as knowledge in the area increases. Antibodies develop as a result of a complex multi-factorial interaction between antigen-presenting cells, T- and B-lymphocytes. Genetic susceptibility of cell surface molecules, such as the major histocompatibility complex, the T-cell receptor and cytokine receptors, as well as various immunomodulatory molecules have a major impact on the outcome. In addition, environmental factors probably influence the risk of inhibitor development. The current concept of inhibitor development is reviewed. A better understanding of the pathophysiological mechanisms involved will facilitate improvement of therapy in the future, and hopefully provide an opportunity to prevent this complication of treatment.}},
author = {{Astermark, Jan}},
issn = {{1351-8216}},
keywords = {{inhibitors; risk factors; genotype; haemophilia}},
language = {{eng}},
pages = {{52--60}},
publisher = {{Wiley-Blackwell}},
series = {{Haemophilia}},
title = {{Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia.}},
url = {{http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16683997&dopt=Abstract}},
volume = {{12 Suppl 3}},
year = {{2006}},
}